vTv Therapeutics Q2 2024 net loss $5.2M; FDA places clinical hold on cadisegliatin T1D trial

vTv Therapeutics Inc.

Net loss $5.2M ($0.81/sh) vs $5.6M ($2.69/sh) in Q2 2023; cash $45.5M up from $9.4M year-end.
FDA placed clinical hold on cadisegliatin T1D program in July; no patients dosed in pivotal trial.
Expanded HPP737 license with Newsoara to global license contingent on $20M upfront fee.
Cantex received Orphan Drug Designation for azeliragon in pancreatic cancer.
R&D expenses decreased to $3.4M from $4.7M; G&A increased to $3.7M from $3.3M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.